title: Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia.
abstract: One hundred and eighteen patients with neurasthenia, as defined by ICD 10 (International Classification of Diseases), participated in a randomised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg). Pivagabine 1800 mg/d was administered orally for four weeks. At the end of the trial, active medication was significantly superior to placebo on the Clinical Global Impression (CGI) improvement of illness scale. In addition, pivagabine treatment reduced the physical and mental fatigability of patients, and increased their sense of well-being.
authors.affiliation: Clinica Neurologica dell'Università di Padova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Pizzolato
authors.forename: A
authors.initials: A
authors.lastname: Cagnin
authors.forename: D
authors.initials: D
authors.lastname: Mancia
authors.forename: P
authors.initials: P
authors.lastname: Caffarra
authors.forename: S
authors.initials: S
authors.lastname: Avanzi
authors.forename: S
authors.initials: S
authors.lastname: Copelli
authors.forename: C
authors.initials: C
authors.lastname: Ciappina
authors.forename: F
authors.initials: F
authors.lastname: Lo Presti
authors.forename: P G
authors.initials: PG
authors.lastname: Spilimbergo
authors.forename: E
authors.initials: E
authors.lastname: D'Antonio
authors.forename: E
authors.initials: E
authors.lastname: Di Costanzo
authors.forename: M
authors.initials: M
authors.lastname: Matrango
authors.forename: P
authors.initials: P
authors.lastname: Pastres
authors.forename: P P
authors.initials: PP
authors.lastname: Urbani
authors.forename: M
authors.initials: M
authors.lastname: Signorino
authors.forename: M
authors.initials: M
authors.lastname: Simoncelli
authors.forename: L
authors.initials: L
authors.lastname: Provinciali
authors.forename: L
authors.initials: L
authors.lastname: Regnicolo
authors.forename: C
authors.initials: C
authors.lastname: Albano
authors.forename: G
authors.initials: G
authors.lastname: Roccatagliata
authors.forename: V
authors.initials: V
authors.lastname: Rubino
authors.forename: S
authors.initials: S
authors.lastname: Cultrera
authors.forename: M
authors.initials: M
authors.lastname: Fracassi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009440:Neurasthenia / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D011619:Psychotropic Drugs; D005680:gamma-Aminobutyric Acid; C038979:pivagabine